Chinese expert consensus on bendamustine for the treatment of lymphoma (2020 version) / 白血病·淋巴瘤

ABSTRACT

Bendamustine, a bifunctionnal molecule with alkylating agent and antimetabolites properties, has shown a better efficacy in many pathological types of lymphomas. Many studies have shown the better efficacy of bendamustine with or without other agents in the treatment of lymphomas including indolent non-Hodgkin lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma. In 2008, bendamustine was approved by Food and Drug Administration of the United States for the treatment of patients with rituximab-resistant indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, bendamustine was not approved for the treatment of lymphomas in China unitil 2018, and most physicians had little clinical experience on the use of this agent. Based on the results of clinical trials of bendamustine in China and the relevant domestic and foreign literatures, the Chinese hematologists and oncologists developed the Chinese expert consensus on bendamustine for the treatment of lymphomas (2020 version).